Pyros Pharmaceuticals introduces VIGAFYDE™, an oral solution containing vigabatrin for treating infantile spasms (IS) in children aged 1 month to 2 years. This premeasured solution simplifies dosing and improves accuracy, addressing the challenges associated with administering medication to infants with this severe seizure disorder.
As the first ready-to-use vigabatrin oral solution, VIGAFYDE™ offers several advantages. It enables caregivers to administer the exact dosage prescribed, reducing the risk of under- or overdosing. This precise dosing is crucial for effectively controlling seizures and preventing potential vision loss, a known risk with vigabatrin therapy.
Recognizing the importance of patient support, Pyros Pharmaceuticals has partnered with AnovoRx as the exclusive specialty pharmacy for VIGAFYDE™. This partnership ensures streamlined medication access, facilitating timely treatment initiation. Additionally, families can access comprehensive support through Pyros Total Care™, a program that guides nurse educators, assistance with reimbursement, and consultations with clinical pharmacists.
VIGAFYDE™ is a significant advancement in IS treatment because it meets the specific needs of affected infants and their caregivers. The ready-to-use formulation eliminates the need for reconstitution, reducing potential errors and ensuring accurate dosing. This user-friendly format enhances compliance, increasing the likelihood of successful treatment outcomes.
Infantile spasm is a rare and serious form of epilepsy that requires early and accurate diagnosis and timely intervention. VIGAFYDE™ empowers healthcare professionals with a safe and effective treatment option, providing hope for improved outcomes in young patients battling this challenging condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
